NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

泌尿道感染(UTI)治療的全球市場(2020年∼2024年)

Global Urinary Tract Infection (UTI) Treatment Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 979888
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
泌尿道感染(UTI)治療的全球市場(2020年∼2024年) Global Urinary Tract Infection (UTI) Treatment Market 2020-2024
出版日期: 2020年12月18日內容資訊: 英文 120 Pages
簡介

泌尿道感染治療的市場規模在2020年∼2024年的預測期間內,預計將以2%的年複合成長率增長,並成長到7億8,671萬美元。泌尿道感染治療市場相關之本報告提供整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

這份報告提供泌尿道感染(UTI)治療的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,病各類型·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2019年)
  • 市場預測(2019年∼2024年)

波特的五力分析

病各類型

  • 市場區隔
  • 各疾病類型比較
  • 不複雜的UTI
  • 複雜的UTI
  • 各疾病類型的市場機會

客戶形勢

各地區

  • 各地區市場區隔
  • 各地區比較
  • 亞洲
  • 歐洲
  • 北美
  • 其他地區
  • 主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abbott Laboratories
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.

附錄

目錄
Product Code: IRTNTR46392

Global Urinary Tract Infection Treatment Market 2020-2024

Technavio has been monitoring the urinary tract infection treatment market and it is poised to grow by $ 786.71 mn during 2020-2024 progressing at a CAGR of 2% during the forecast period. Our report on urinary tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the relation of UTI with several other factors leading to rising incidence rate of UTI, rising cases of hospital-acquired UTI and unmet demand due to lack of available treatment for MDR microorganisms. In addition, relation of UTI with several other factors leading to rising incidence rate of UTI is anticipated to boost the growth of the market as well.

The urinary tract infection treatment market analysis includes type segment and geographical landscapes.

Technavio's urinary tract infection treatment market is segmented as below:

By Type

  • Uncomplicated UTI
  • Complicated UTI

By Geographical Landscapes

  • Asia
  • Europe
  • North America
  • ROW

This study identifies the growing awareness of controlled usage of antibiotics as one of the prime reasons driving the urinary tract infection treatment market growth during the next few years. Also, rising R&D for effective treatment against superbugs/MDR microorganisms and advent of new therapies for UTI treatment will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on urinary tract infection treatment market covers the following areas:

  • Urinary tract infection treatment market sizing
  • Urinary tract infection treatment market forecast
  • Urinary tract infection treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading urinary tract infection treatment market vendors that include Abbott Laboratories, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Cipla Inc., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., and SHIONOGI Co. Ltd.. Also, the urinary tract infection treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Disease type

  • Market segments
  • Comparison by Disease type
  • Uncomplicated UTI - Market size and forecast 2019-2024
  • Complicated UTI - Market size and forecast 2019-2024
  • Market opportunity by Disease type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Uncomplicated UTI - Market size and forecast 2019-2024 ($ million)
  • 24: Uncomplicated UTI - Year-over-year growth 2019-2024 (%)
  • 25: Complicated UTI - Market size and forecast 2019-2024 ($ million)
  • 26: Complicated UTI - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Other1
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: Asia - Market size and forecast 2019-2024 ($ million)
  • 32: Asia - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Abbott Laboratories - Overview
  • 48: Abbott Laboratories - Business segments
  • 49: Abbott Laboratories - Key offerings
  • 50: Abbott Laboratories - Key customers
  • 51: Abbott Laboratories - Segment focus
  • 52: AbbVie Inc. - Overview
  • 53: AbbVie Inc. - Business segments
  • 54: AbbVie Inc. - Key offerings
  • 55: AbbVie Inc. - Key customers
  • 56: AbbVie Inc. - Segment focus
  • 57: Bayer AG - Overview
  • 58: Bayer AG - Business segments
  • 59: Bayer AG - Key offerings
  • 60: Bayer AG - Key customers
  • 61: Bayer AG - Segment focus
  • 62: Boehringer Ingelheim International GmbH - Overview
  • 63: Boehringer Ingelheim International GmbH - Business segments
  • 64: Boehringer Ingelheim International GmbH - Key offerings
  • 65: Boehringer Ingelheim International GmbH - Key customers
  • 66: Boehringer Ingelheim International GmbH - Segment focus
  • 67: Cipla Inc. - Overview
  • 68: Cipla Inc. - Business segments
  • 69: Cipla Inc. - Key offerings
  • 70: Cipla Inc. - Key customers
  • 71: Cipla Inc. - Segment focus
  • 72: GlaxoSmithKline Plc - Overview
  • 73: GlaxoSmithKline Plc - Business segments
  • 74: GlaxoSmithKline Plc - Key offerings
  • 75: GlaxoSmithKline Plc - Key customers
  • 76: GlaxoSmithKline Plc - Segment focus
  • 77: Merck & Co. Inc. - Overview
  • 78: Merck & Co. Inc. - Business segments
  • 79: Merck & Co. Inc. - Key offerings
  • 80: Merck & Co. Inc. - Key customers
  • 81: Merck & Co. Inc. - Segment focus
  • 82: Novartis AG - Overview
  • 83: Novartis AG - Business segments
  • 84: Novartis AG - Key offerings
  • 85: Novartis AG - Key customers
  • 86: Novartis AG - Segment focus
  • 87: Pfizer Inc. - Overview
  • 88: Pfizer Inc. - Business segments
  • 89: Pfizer Inc. - Key offerings
  • 90: Pfizer Inc. - Key customers
  • 91: Pfizer Inc. - Segment focus
  • 92: SHIONOGI Co. Ltd. - Overview
  • 93: SHIONOGI Co. Ltd. - Business segments
  • 94: SHIONOGI Co. Ltd. - Key offerings
  • 95: SHIONOGI Co. Ltd. - Key customers
  • 96: SHIONOGI Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations